The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / NIAMS’ Intramural Research Programs Foster Spirit of Discovery

NIAMS’ Intramural Research Programs Foster Spirit of Discovery

March 1, 2015 • By Gretchen Henkel

  • Tweet
  • Email
Print-Friendly Version / Save PDF

You Might Also Like
  • Competition on Another Pitch: Capture the World Cup Spirit to Drive Rheumatology Discovery
  • ACR/ARHP 2016 Research Conferences Foster Exchanges with Colleagues Before Annual Meeting Start
  • Funding Sources for Scientific Discovery, Medical Research
Explore This Issue
March 2015
Also By This Author
  • NYU Langone’s Division of Rheumatology in Manhattan Advances Its Mission to Understand Rheumatic Diseases, Improve Patient Outcomes
Dr. O’Shea, MD, NIAMS
Dr. O’Shea

Three factors contribute to the NIAMS Intramural Program’s stature as both a training and an innovation center, says Dr. Kastner: investigators are hired to develop their own programs, driven by their own interests and curiosity, without the need to apply for grants; high-risk, high-reward projects are encouraged; and the leadership throughout NIAMS’ history has set the tone for research excellence.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

 

 

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Kastner
Dr. Kastner

’Twas Ever Thus

Although there have been many transformations in the structure of the NIH since 1950 when the first arthritis program was established, the spirit of discovery has been a constant. Paul H. Plotz, MD, MACR, NIH scientist emeritus and and winner of the ACR Presidential Gold Medal in 2013, first joined the program in 1965 and spent his entire career there, except for a two-year fellowship at the National Institute for Medical Research at Mill Hill, London, from 1968–70. During his 50 years with the program, he has served as chief of the Arthritis and Rheumatism Branch, acting scientific director and acting deputy director, in addition to conducting his own research. “I’ve lived through about six different names [of the Institute],” he jokes. (The current NIAMS was established in 1986; to learn more about the key events in NIAMS’ history and legislative chronology establishing the Institute, visit http://www.nih.gov/about/almanac/organization/NIAMS.htm.)

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE
Dr. Plotz
Dr. Plotz

Dr. Plotz enumerates the achievements of some of the early leaders at the Institute, including John Decker, MD, “responsible for the shape and flavor of the rheumatology program in the institute”; and Henry Metzger, MD, who is a member of the National Academy of Sciences and responsible for characterizing the structure of IgM.

During those early days, Dr. Plotz also worked alongside other greats, such as gout experts J. Edwin Seegmiller, MD, and William M. Kelley, MD. And before Dr. Plotz arrived, research by Joseph Bunim, MD, and Watson Buchanan, MD, resulted in the publication of a seminal article on the clinical characteristics of Sjögren’s syndrome.

“Historically, NIAMS has played a key role in the treatment of lupus nephritis, through methods developed here in large longitudinal studies. And very good genetics work is being done in various parts of our Institute,” Dr. Plotz adds.

Dr. Siegel (right) in the lab, where breakthroughs in the treatment of autoimmune diseases have been made.
Dr. Siegel (right) in the lab, where breakthroughs in the treatment of autoimmune diseases have been made.

Above: Dr. Siegel (left) examines a patient in the clinic. He notes the use of cyclophosphamide in vasculitis and lupus, and the first use of methotrexate for nonmalignant disease, were pioneered at the NIH. Below: Dr. O’Shea

No Resting on Laurels

Richard Siegel, MD, PhD, NIAMS clinical director and chief, Immunoregulation Section, Autoimmunity Branch, notes that, in recent decades, other advancements in the understanding and treatment of rheumatic disease have emanated from the NIH. For example, the use of cyclophosphamide in vasculitis and, later, in lupus and the first use of methotrexate for nonmalignant disease were both pioneered at the NIH.

Pages: 1 2 3 4 5 | Single Page

Filed Under: Profiles Tagged With: excellence, Henkel, NIAMS, rheumatology, TrainingIssue: March 2015

You Might Also Like:
  • Competition on Another Pitch: Capture the World Cup Spirit to Drive Rheumatology Discovery
  • ACR/ARHP 2016 Research Conferences Foster Exchanges with Colleagues Before Annual Meeting Start
  • Funding Sources for Scientific Discovery, Medical Research
  • ACR Research and Education Foundation Meets with NIAMS and AF to Discuss Funding

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)